MedTrace Logo

Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025)

NCT01527370 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2018-09-18

Study results available
· View outcomes & findings →

Summary

This study will determine if ZOSTAVAX™ is safe, tolerable, and immunogenic in healthy adults in India.

Conditions

  • Herpes Zoster
  • Shingles

Interventions

BIOLOGICAL

Zoster Vaccine Live

One approximately 0.65 mL injection subcutaneously on Day 1

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2013-04-09
Completion
2013-04-09

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01527370 on ClinicalTrials.gov